echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > FDA issues warning letter involving lianhua-clearing capsules

    FDA issues warning letter involving lianhua-clearing capsules

    • Last Update: 2020-07-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On June 29, the FDA issued a warning letter saying that the website of SuperHealthGuard and Loyal Great International Ltd., a company based in Hong Kong, China, could sell the co-op capsules to the United States, directly labeling the product to alleviate, prevent, treat, diagnose or cure COVID-19the FDA and the Federal Trade Commission (FTC) argued that even the capsules were not approved by the FDA, in violation of Section 21 of the Federal Food, Drug and Cosmetic Act, in violation of Section 21 of the Federal Food, Drug and Cosmetic Act, section 505 (a) of USCIn addition, the product is a mislabeled drug under Section 502 of the FD-C Act, Section 21, Section 352, of the United States CodeSections 301 (a) and (d) of the FD-C Act, 21 USC,331 (a) and (d) prohibit the introduction of the product into interstate commercecurrently in the world, the outbreak of new crown pneumonia is still not over, and the FDA is taking urgent steps to protect consumers from certain drugs that are not approved or authorized by the FDA, such as those that claim to reduce, prevent, treat, diagnose or cure COVID-19So the FDA issued a warning letter asking the company to take immediate action to correct the violationAt the same time, the FDA also reminds consumers to be cautious about buying products that are not approved or authorized by the FDA.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.